Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lamictal IR Experience Impresses Advisory Committee, Not XR Trial Design

This article was originally published in The Pink Sheet Daily

Executive Summary

Committee members recommend Lamictal XR as a monotherapy for partial seizures, relying on the knowledge that the immediate-release version of the drug works for the indication.

You may also be interested in...



FDA Advisory Committee Waivers Reflect Recruitment Challenges

Recent waivers allowing the participation of outside experts at drug-related advisory committee meetings reflect FDA's difficulties in finding qualified individuals to provide advice on specialized topics.

FDA Advisory Committee Waivers Reflect Recruitment Challenges

Recent waivers allowing the participation of outside experts at drug-related advisory committee meetings reflect FDA's difficulties in finding qualified individuals to provide advice on specialized topics.

Lamictal XR's Monotherapy Claim May Spur More Historical Control Trials

GlaxoSmithKline’s anti-epileptic drug Lamictal XR gained approval for conversion to monotherapy without any post-marketing commitments despite concerns about the novel trial design employed for the application.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS071935

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel